Price movement over the last 24 hours
Goldman Sachs Physical Gold ETF vs Nuvalent Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.3, while Nuvalent Inc trades at $123.81 (market cap $9.80B). The key difference: Nuvalent Inc is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | NUVL | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $53.21 | $123.77 |
52-Week Low | $32.29 | $72.16 |
Market Cap | — | $9.80B |
Enterprise Value | — | $8.51B |
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.
Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.
Nuvalent (NUVL) trades at $123.72, down slightly by 0.01% on the day, with a price-to-book ratio of 8.34. The stock exhibits a bullish technical trend, supported by strong moving averages, though RSI levels indicate overbought conditions. Recent financials show negative profitability, with a net loss of $425.38 million in 2025 and negative operating cash flow, but the company secured $515.34 million in financing. A major development is the pending $10.6 billion acquisition by GSK at $124 per share, announced in June 2026, which has driven significant investor attention and legal scrutiny over fairness.
The outlook for NUVL is heavily influenced by the GSK acquisition, offering a near-term exit at $124 per share. Risks include ongoing shareholder investigations into the deal's fairness and the company's persistent losses. Analyst sentiment is mixed, with 42% recommending buy and 58% hold, reflecting uncertainty around the acquisition's completion and valuation. Investors should monitor regulatory approvals and any competing offers that may emerge, as these will determine final shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →